UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

British journal of cancer, 2012-02, Vol.106 (5), p.839-845

2012

Volltextzugriff (PDF)

Cutting edge: FcR-like 6 is an MHC class II receptor

The Journal of immunology (1950), 2010-07, Vol.185 (1), p.23-27

2010

Volltextzugriff (PDF)

FCRL3 promotes TLR9‐induced B‐cell activation and suppresses plasma cell differentiation

European journal of immunology, 2013-11, Vol.43 (11), p.2980-2992

2013

Volltextzugriff (PDF)

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide

Journal of clinical oncology, 1997-06, Vol.15 (6), p.2385-2393

1997

Volltextzugriff (PDF)

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Haematologica (Roma), 2016-07, Vol.101 (7), p.e295-e298

2016

Volltextzugriff (PDF)

FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia

European journal of immunology, 2008-11, Vol.38 (11), p.3159-3166

2008

Volltextzugriff (PDF)

Abstract P2-02-12: Cell free DNA analysis identifies actionable ERBB2 amplifications in patients with HER2 negative breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-02-12

2018

Volltextzugriff (PDF)

Fc receptor-like proteins (FCRL): immunomodulators of B cell function

Advances in experimental medicine and biology, 2007, Vol.596, p.155

2007

Volltextzugriff (PDF)

Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET)

Annals of oncology, 2016-10, Vol.27, p.vi450-vi450

2016

Volltextzugriff (PDF)

Response to Comment on “Cutting Edge: FcR-Like 6 Is an MHC Class II Receptor”

The Journal of immunology (1950), 2010-11, Vol.185 (9), p.4965-4966

2010

Volltextzugriff (PDF)

Hepatic Artery Administration of Paclitaxel

Cancer investigation, 1999, Vol.17 (2), p.118-120

1999

Volltextzugriff (PDF)

A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.7001-7001

2011

Volltextzugriff (PDF)

Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13531-e13531

2010

Volltextzugriff (PDF)

A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3064-3064

2011

Volltextzugriff (PDF)

FCRL 3 promotes TLR 9‐induced B ‐cell activation and suppresses plasma cell differentiation

European journal of immunology, 2013-11, Vol.43 (11), p.2980-2992

2013

Volltextzugriff (PDF)

A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3576-3576

2009

Volltextzugriff (PDF)

Bone Marrow Origin of a B-Cell Lymphoma

Blood, 1988-07, Vol.72 (1), p.94-101

1988

Volltextzugriff (PDF)

A Critical Appraisal of Late Complications of Prepectoral Versus Subpectoral Breast Reconstruction Following Nipple-Sparing Mastectomy

Plastic and reconstructive surgery. Global open, 2020-10, Vol.8 (9S), p.20-20

2020

Volltextzugriff (PDF)

Translation of gene expression profiles into a nine antibody IHC multivariate index assay for colorectal carcinoma

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.21042-21042

2007

Volltextzugriff (PDF)

Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.7643-7643

2007

Volltextzugriff (PDF)

Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15622-15622

2007

Volltextzugriff (PDF)

COMBINATION OF TGR‐1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA

Hematological oncology, 2017-06, Vol.35 (S2), p.266-267

2017

Volltextzugriff (PDF)

CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL

Hematological oncology, 2017-06, Vol.35 (S2), p.112-113

2017

Volltextzugriff (PDF)

Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.14565-14565

2008

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(94)

Publikationsform

Artikel
(108)
Dissertationen
(1)

Sprache

Englisch
(109)

Erscheinungsjahr

n.n

Thema

Humans
(38)
Life Sciences & Biomedicine
(36)
Science & Technology
(36)
Male
(25)
Middle Aged
(20)
Female
(19)
Adult
(16)
Aged
(15)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Oncology
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Hematology
(8)
Aged, 80 And Over
(7)
Chronic Lymphocytic Leukemia
(7)
Immunology
(7)
Adolescent
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)
Chemotherapy
(6)
Etoposide - Administration & Dosage
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

Cutting edge: FcR-like 6 is an MHC class II receptor

FCRL3 promotes TLR9‐induced B‐cell activation and suppresses plasma cell differentiation

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia

Abstract P2-02-12: Cell free DNA analysis identifies actionable ERBB2 amplifications in patients with HER2 negative breast cancer

Fc receptor-like proteins (FCRL): immunomodulators of B cell function

Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET)

Response to Comment on “Cutting Edge: FcR-Like 6 Is an MHC Class II Receptor”

Hepatic Artery Administration of Paclitaxel

A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC)

Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC)

A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies

FCRL 3 promotes TLR 9‐induced B ‐cell activation and suppresses plasma cell differentiation

A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)

Bone Marrow Origin of a B-Cell Lymphoma

A Critical Appraisal of Late Complications of Prepectoral Versus Subpectoral Breast Reconstruction Following Nipple-Sparing Mastectomy

Translation of gene expression profiles into a nine antibody IHC multivariate index assay for colorectal carcinoma

Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)

Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI)

COMBINATION OF TGR‐1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA

CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL

Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC)

Suchergebnisse filtern